2026-525932-40-00RecruitingPhase 1
An Open-Label, Controlled, Multiple-Dose Phase I Clinical Trial Evaluating the Steady-State Pharmacokinetics, Pharmacodynamics and Safety of SHR-3167 in Subjects With Type 2 Diabetes
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Sept 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- 12 Oct 2026
- Lead sponsor
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Diseases
- Type 2 diabetes
- EU CT number
- 2026-525932-40-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 35
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| PROFIL Institut fuer Stoffwechselforschung GmbH Coordinator of this site? Confirm its status | Neuss | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.